About BIOVERSYS N
Sector
Industry
Headquarters
Basel
Website
Founded
2008
ISIN
CH0210362643
FIGI
BBG01RXCPP94
BioVersys AG is a clinical stage biopharmaceutical company, which engages in identifying, development, and commercializing novel antibacterial products for infections caused by multi-drug resistant (MDR) bacteria. It is involved in the research and development programs that address nosocomial infections of Acinetobacter baumannii and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BIOV is 34.000 CHF — it has increased by 4.09% in the past 24 hours. Watch BIOVERSYS N stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange BIOVERSYS N stocks are traded under the ticker BIOV.
BIOV stock has fallen by −4.18% compared to the previous week, the month change is a −4.18% fall, over the last year BIOVERSYS N has showed a −6.85% decrease.
No, BIOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOVERSYS N stock right from TradingView charts — choose your broker and connect to your account.